Quell utilizes NeuroMetrix's proprietary non-invasive neurostimulation technology to provide relief from chronic pain, such as due to diabetes, sciatica, fibromyalgia and degenerative knee conditions.
NeuroMetrix on Tuesday announced that its wearable technology for treatment of chronic pain received 510(k) clearance from the Food and Drug Administration for over-the-counter use.
A survey by the National Pain Foundation of more than 300 people who live with chronic pain is shedding light on how chronic pain sufferers are treated by their healthcare providers.
Last year the Food and Drug Administration warned parents against using the ingredient benzocaine in children to relieve oral pain.
A movement toward a more team-based, coordinated approach to patient care has helped drive increased demand for advance practice clinicians, as well as an increase in salaries for this group, according to findings of a recently released survey.
Thermionics’ ThermiPaq products, which now sport an eye-catching yellow “Control Your Pain!” panel as part...
McKesson has updated its Connect-Rx software, which now features improved functionality and work flow for...